Evacetrapib is a cholesterol ester transfer protein (CETP) inhibitor that exhibits anti-atherosclerotic activity. This compound increases cholesterol efflux capacity. Evacetrapib also increases levels of HDL and ApoA1 and decreases levels of LDL and ApoB.
| Purity | ≥98% |
|---|---|
| Formula | C31H36F6N6O2 |
| Formula Wt. | 638.66 |
| Synonym | LY2484595 |
| Appearance | White Powder |
| Store Temp | -20°C |
|---|
| Info Sheet | E8401 Info Sheet PDF |
|---|
Nicholls SJ, Ruotolo G, Brewer HB, et al. Cholesterol Efflux Capacity and Pre-Beta-1 HDL Concentrations Are Increased in Dyslipidemic Patients Treated With Evacetrapib. J Am Coll Cardiol. 2015 Nov 17;66(20):2201-10. PMID: 26564598.
Suico JG, Wang MD, Friedrich S, et al. Effects of the cholesteryl ester transfer protein inhibitor evacetrapib on lipoproteins, apolipoproteins and 24-h ambulatory blood pressure in healthy adults. J Pharm Pharmacol. 2014 Nov;66(11):1576-85. PMID: 24961753.
Cao G, Beyer TP, Zhang Y, et al. Evacetrapib is a novel, potent, and selective inhibitor of cholesteryl ester transfer protein that elevates HDL cholesterol without inducing aldosterone or increasing blood pressure. J Lipid Res. 2011 Dec;52(12):2169-76. PMID: 21957197.
